Home › Breast Cancer › Maryland
Breast Cancer clinical trials in Maryland
68 studies for Breast Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 30, 2026 · NCT07619534Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Maryland Proton Treatment Center, Baltimore
RecruitingPhase 2
Ages 50 and older · Women · Updated Sep 29, 2026 · NCT01766297Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Maryland Proton Treatment Center, Baltimore
RecruitingPhase 3
Ages 19 and older · Women · Updated Sep 29, 2026 · NCT05856773Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Mercy Medical Center, Baltimore
- Maryland Oncology Hematology P A, Silver Spring
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 29, 2026 · NCT05827081Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Sep 28, 2026 · NCT03412877Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 and older · All sexes · Updated Sep 28, 2026 · NCT01441089Genomic Services Research Program
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
1 Month – 105 Years · All sexes · Updated Sep 28, 2026 · NCT02595957Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT00034216A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
- Holy Cross Hospital ( Site 0073), Silver Spring
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312176A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Annapolis
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Sep 22, 2026 · NCT01174121A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- United Theranostics, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Medstar Research Institute, Hyattsville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05894239Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07340541ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Agnes Hospital, Clinical Research Center, Baltimore
- Maryland Oncology Hematology P.A., Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Maryland Oncology Hematology - Annapolis, Annapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07100106Cardiometabolic Screening Program
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Recruiting
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05386719Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Velocity Clinical Research, Annapolis
- University of Maryland, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06790693PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06245889Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612The Vanguard Study: Testing a New Way to Screen for Cancer
- Walter Reed National Military Medical Center, Bethesda
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- and 10 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- and 17 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Sep 2, 2026 · NCT05879926A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Maryland Oncology Hematology, Laurel
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07102381A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06764940A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
Recruiting
Ages 18 to 120 · All sexes · Updated Aug 21, 2026 · NCT07067138Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06500481Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 72 · All sexes · Updated Aug 13, 2026 · NCT02830724A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Walter Reed National Military Medical Center, Bethesda
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07140172Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Maryland Oncology Hematology, Annapolis
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- and 14 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Aug 4, 2026 · NCT06748222Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.